Difference between revisions of "Tranexamic acid (Cyklokapron)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "Drugs@FDA" to "Drugs @ FDA") |
||
| Line 8: | Line 8: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*1986-12-30: Initial FDA approval | *1986-12-30: Initial FDA approval | ||
| − | *2008-12-22 (oldest label available at Drugs@FDA): Indicated in patients with hemophilia for short-term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. | + | *2008-12-22 (oldest label available at Drugs @ FDA): Indicated in patients with hemophilia for short-term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. |
==Also known as== | ==Also known as== | ||
Latest revision as of 12:44, 5 June 2023
Mechanism of action
Tranexamic acid is a competitive inhibitor of plasminogen activation, and at much higher concentrations, a noncompetitive inhibitor of plasmin, i.e., actions similar to aminocaproic acid. Tranexamic acid is about 10 times more potent in vitro than aminocaproic acid.
Diseases for which it is used
History of changes in FDA indication
- 1986-12-30: Initial FDA approval
- 2008-12-22 (oldest label available at Drugs @ FDA): Indicated in patients with hemophilia for short-term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction.
Also known as
- Brand names: Amixam, Cyklokapron, Hemostan, Prexam, Temsy, Tranofast